| scholarly article | Q13442814 |
| P50 | author | Detlef Schuppan | Q17418245 |
| P2093 | author name string | Martin Zeitz | |
| Hans Scherübl | |||
| Alexander Huether | |||
| Andreas P Sutter | |||
| Michael Höpfner | |||
| P2860 | cites work | Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line | Q40298371 |
| P433 | issue | 6 | |
| P304 | page(s) | 1008-1016 | |
| P577 | publication date | 2004-12-01 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. | |
| P478 | volume | 41 |
| Q33987671 | A systems biology-based classifier for hepatocellular carcinoma diagnosis |
| Q90475067 | Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer |
| Q57023556 | Benzofuran-appended 4-aminoquinazoline hybrids as epidermal growth factor receptor tyrosine kinase inhibitors: synthesis, biological evaluation and molecular docking studies |
| Q39869486 | Chromogenic in situ hybridization analysis of Epidermal Growth Factor Receptor gene/chromosome 7 numerical aberrations in hepatocellular carcinoma based on tissue microarrays |
| Q42546774 | Classifier of cross talk genes predicts the prognosis of hepatocellular carcinoma |
| Q35231826 | Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells |
| Q36147887 | Comparison of Helicobacter bilis-Associated Protein Expression in Huh7 Cells Harbouring HCV Replicon and in Replicon-Cured Cells |
| Q34539948 | Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines? |
| Q91480122 | Cyclooxygenase-2 in gastrointestinal malignancies |
| Q37378968 | Cyclooxygenase-2 prevents fas-induced liver injury through up-regulation of epidermal growth factor receptor |
| Q35566362 | Cytosolic phospholipase A(2)α protects against Fas- but not LPS-induced liver injury |
| Q52822419 | Design, synthesis and evaluation of alkylphosphocholine-gefitinib conjugates as multitarget anticancer agents. |
| Q36519010 | Dysregulation of growth factor signaling in human hepatocellular carcinoma. |
| Q26771265 | EGFR Signaling in Liver Diseases |
| Q39362619 | EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib |
| Q34282375 | EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation |
| Q40238980 | EGFR is phosphorylated at Ty845 in hepatocellular carcinoma |
| Q33248446 | Effect of blocking IGF-I receptor on growth of human hepatocellular carcinoma cells |
| Q38161361 | Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. |
| Q34382777 | Exploiting novel molecular targets in gastrointestinal cancers. |
| Q37644850 | FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop |
| Q53630404 | Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells. |
| Q36446915 | Gefitinib: an adverse effects profile |
| Q43141124 | Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer |
| Q34568677 | Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III |
| Q37821305 | Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. |
| Q34499002 | Hepatitis C virus-mediated angiogenesis: molecular mechanisms and therapeutic strategies. |
| Q29615767 | Hepatocellular carcinoma pathogenesis: from genes to environment |
| Q59789600 | Icotinib inhibits the proliferation of hepatocellular carcinoma cells in vitro and in vivo dependently on EGFR activation and PDL1 expression |
| Q37003601 | Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma |
| Q41434771 | Impact of epidermal growth factor receptor protein and gene alteration on Taiwanese hepatocellular carcinomas |
| Q41169751 | In vivo and in vitro effects of QHF combined with chemotherapy on hepatocellular carcinoma |
| Q30372076 | In vivo photoacoustic tomography of EGFR overexpressed in hepatocellular carcinoma mouse xenograft. |
| Q39281043 | Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells |
| Q89861316 | Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma |
| Q37370027 | Molecular targeted therapy for hepatocellular carcinoma |
| Q36740642 | New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system |
| Q36883798 | New perspectives and strategy research biomarkers for hepatocellular carcinoma. |
| Q36519041 | New therapies for hepatocellular carcinoma. |
| Q39692519 | Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours |
| Q38615458 | Novel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-α: impact on gastrointestinal cancers driven by secondary bile acids. |
| Q34940971 | Novel therapeutic strategies for targeting liver cancer stem cells |
| Q33635033 | Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma. |
| Q61814436 | Oxazole-Bridged Combretastatin A-4 Derivatives with Tethered Hydroxamic Acids: Structure⁻Activity Relations of New Inhibitors of HDAC and/or Tubulin Function |
| Q34364217 | Peritumoral small ephrinA5 isoform level predicts the postoperative survival in hepatocellular carcinoma |
| Q39799281 | Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response |
| Q36247086 | Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria |
| Q36233866 | Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers |
| Q64097554 | Promotion of growth factor signaling as a critical function of β-catenin during HCC progression |
| Q90094407 | Reimaging biological barriers affecting distribution and extravasation of PEG/peptide- modified liposomes in xenograft SMMC7721 tumor |
| Q40238825 | Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. |
| Q38487106 | Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development |
| Q37413127 | Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma. |
| Q64890999 | Synthesis, Biological Evaluation and Molecular Docking of Novel Indole-Aminoquinazoline Hybrids for Anticancer Properties. |
| Q38992642 | Synthesis, molecular docking and biological evaluation of glycyrrhizin analogs as anticancer agents targeting EGFR. |
| Q37702506 | Targeted therapy in gastrointestinal malignancies |
| Q37674624 | Targeted therapy of hepatocellular cancer. |
| Q64086947 | Targeting TF-AKT/ERK-EGFR Pathway Suppresses the Growth of Hepatocellular Carcinoma |
| Q28820734 | The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models |
| Q51093729 | The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis. |
| Q35081944 | The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. |
| Q37773788 | The role of signaling pathways in the development and treatment of hepatocellular carcinoma |
| Q38008950 | Translational medicine in hepatocellular carcinoma |
| Q37686529 | Tyrosine kinase inhibitors to treat liver cancer |
| Q39769976 | Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer |
| Q79317745 | [Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma] |
| Q80554209 | [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology] |
Search more.